Metraipolis › archive › dc_0febdec06df5

Aducanumab — Wikipedia (en)

Source: Wikipedia (en)
Original: https://en.wikipedia.org/wiki/Aducanumab
License (as archived): CC-BY-SA-4.0
Archived: 2026-11-07T16:06:08.368Z
SHA-256 of the archived text: 544ed7f78579b0ccffa9a78b1ffafa123dc995b31ffde187b04f0f586bd5e9de
Stable URL of this page: https://metraipolis.com/documento/dc_0febdec06df5

How to cite

Aducanumab — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Aducanumab (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_0febdec06df5 (Metraipolis archive dc_0febdec06df5, sha256 544ed7f78579b0ccffa9a78b1ffafa123dc995b31ffde187b04f0f586bd5e9de)

BibTeX

@misc{dc0febdec06df5,
  title = {Aducanumab — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Aducanumab},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_0febdec06df5; sha256 544ed7f78579b0ccffa9a78b1ffafa123dc995b31ffde187b04f0f586bd5e9de},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Aducanumab. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion. Aducanumab was approved for medical use in the United States by the Food and Drug Administration (FDA) in June 2021, in a controversial decision that led to the resignation of three advisers to the FDA in the absence of evidence that the medication is effective. The FDA stated that it represents a first-of-its-kind treatment approved for Alzheimer's disease and that it is the first new treatment approved for Alzheimer's since 2003. Aducanumab's approval is controversial for numerous reasons including ambiguous clinical trial results regarding efficacy, the high cost of the medication and the very high rate of serious adverse events. The FDA considers it to be a first-in-class medication. In November 2020, a panel of outside experts for the FDA concluded that a pivotal study of aducanumab failed to show strong evidence that the medication worked, citing questionable efficacy and multiple red flags found with the data analysis. There were also significant health risks associated with the medication; brain swelling or brain bleeding was found in 41% of patients enrolled in the studies. Nevertheless, the medication was approved under the FDA's accelerated approval pathway, and the FDA requires Biogen to perform follow-up reviews to assure the medication is a safe and effective treatment for Alzheimer's disease. The Office of Inspector General, US Department of Health and Human Services was asked to investigate interaction between the drug company and the FDA prior to the medication's approval. Biogen abandoned the drug in January 2024, for financial reasons.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Aducanumab» — https://en.wikipedia.org/wiki/Aducanumab
Wikidata Q15708278: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q15708278
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Aducanumab?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1384062483, consultata il 2026-11-07T16:02:03.761Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 797eba2c42963495d0ec2654145954edcb082a36b71b2f829b5b6342a72a56a4